Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Adv Drug Deliv Rev. 2021 Oct 8;179:113996. doi: 10.1016/j.addr.2021.113996

Table 2.

Current FDA approved nanocarrier antibiotics.

Existing Nanomedicines to treat Infectious Diseases
Drug name Drug type Target Benefit
AmBisome A unilamellar liposome preparation of amphotericin B[61] Fungi The liposomal preparation decreases the drug volume of distribution leading to a dual benefit:

  1. Increased Cmax and AUC

  2. Decreased kidney concentrations, and therefore, decreased toxicity[70]
Arikayce An amikacin liposome inhalation suspension[67] Nontuberculous mycobacterium Inhalation of liposomal preparation offers the advantage of directed delivery to the lung macrophages. The amikacin-laden macrophages then act as a drug depot, allowing increased intracellular and extracellular bacterial killing. Arikayce has a 3-fold increased conversion to NTM negative sputum rate, as compared to standard multidrug antibiotic regimen[71].